Mycoplasma pneumoniae cells, small bacteria that are naturally adapted to the human lung.
Credit: María Lluch / CRG
Researchers at the Center for Genomic Regulation (CRG) and Pulmobiotics SL have created the first ‘living medicine’ to treat antibiotic-resistant bacteria growing on the surfaces of medical implants. The researchers created the treatment by removing a common bacteria’s ability to cause disease and repurposing it to attack harmful microbes instead.
The experimental treatment was tested on infected catheters in vitro, ex vivo and in vivo, successfully treating infections across all three testing methods. According to the authors, injecting the therapy under the skin of mice treated infections in 82% of the treated animals.
The findings are an important first step for the development of new treatments for infections affecting medical implants such as catheters, pacemakers and prosthetic joints. These are highly resistant to antibiotics and account for 80% of all infections acquired in hospital settings.
The study is published today in the journal Molecular Systems Biology . This work has been supported by the “la Caixa” Foundation through the CaixaResearch Health call, the European Research Council (ERC), the MycoSynVac project under the EU’s Horizon 2020 research and innovation program, the Generalitat de Catalunya and the Instituto de Salud Carlos III .
The new treatment specifically targets biofilms, colonies of bacterial cells that stick together on a surface. The surfaces of medical implants are ideal growing conditions for biofilms, where they form impenetrable structures that prevent antibiotics or the human immune system from destroying the bacteria embedded within. Biofilm-associated bacteria can be a thousand times more resistant to antibiotics than free-floating bacteria.
Staphylococcus aureus is one of the most common species of biofilm-associated bacteria. S. aureus infections do not respond to conventional antibiotics, requiring patients to surgically remove any infected medical implants. Alternative therapies include the use of antibodies or enzymes, but these are broad-spectrum treatments that are highly toxic for normal tissues and cells, causing undesired side effects.
The authors of the study hypothesized that introducing living organisms that directly produce enzymes in the local vicinity of biofilms is a safer and cheaper way of treating infections. Bacteria are an ideal vector, as they have small genomes that can be modified using simple genetic manipulation.
The researchers chose to engineer Mycoplasma pneumoniae, a common species of bacteria that lacks a cell wall, making it easier to release the therapeutic molecules that fight infection while also assisting it in evading detection from the human immune system. Other advantages of using M. pneumoniae as a vector include its low risk of mutating new abilities, and its inability to transfer any of its modified genes to other microbes living nearby.
M. pneumoniae was first modified so that it would not cause illness. Further tweaks made it produce two different enzymes that dissolve biofilms and attacks the cell walls of the bacteria embedded within. The researchers also modified the bacteria so that it secretes antimicrobial enzymes more efficiently.
The researchers first aim to use the modified bacteria to treat biofilms building around breathing tubes, as M. pneumoniae is naturally adapted to the lung. “Our technology, based on synthetic biology and live biotherapeutics, has been designed to meet all safety and efficacy standards for application in the lung, with respiratory diseases being one of the first targets. Our next challenge is to address high-scale production and manufacturing, and we expect to start clinical trials in 2023, ”says María Lluch, co-corresponding author of the study and Chief Science Officer of Pulmobiotics.
The modified bacteria may also have long-term applications for other diseases. “Bacteria are ideal vehicles for ‘living medicine’ because they can carry any given therapeutic protein to treat the source of a disease. One of the great benefits of the technology is that once they reach their destination, bacterial vectors offer continuous and localized production of the therapeutic molecule. Like any vehicle, our bacteria can be modified with different payloads that target different diseases, with potentially more applications in the future, ”says ICREA Research Professor Luis Serrano, Director of the CRG and co-author of the study.
Original Article: Researchers create ‘living medicine’ to treat drug-resistant infections
More from: Center for Genomic Regulation
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- What will living with COVID mean for the coming years? The common cold may provide clueson August 2, 2022 at 11:10 am
The pandemic may feel endless, but the COVID-19 virus remains in the infancy of scientific understanding. How frequently people should expect to catch the virus — it could be every 9 months, based on ...
- From the archives: Sunita Puri on living — and dying — wellon August 2, 2022 at 10:30 am
This Friday’s Big Books and Bold Ideas will feature a conversation between host Kerri Miller and author Caleb Wilde, a sixth-generation funeral director who’s written a new book, “All the Ways Our ...
- Living Day By Dayon August 2, 2022 at 9:32 am
AM, I was surprised that I got through the day without being very sleepy. It was especially weird because I had been having allergic reactions all night and took a lot of Benadryl. It calmed the ...
- 'Living' at the Edge of Innovation in Healthcareon August 2, 2022 at 1:14 am
Mdisrupt's CEO and founder, Ruby Gadelrab shares her thoughts on the medtech industry and discusses her formula to having a strong work/life balance.
- The Journal of Nuclear Medicine provides first-hand account of practicing medicine in wartime Ukraineon August 1, 2022 at 5:14 pm
The Journal of Nuclear Medicine has published a first-hand account of the daily practice of nuclear medicine and molecular imaging during the ongoing war in Ukraine.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Antibiotic-resistant bacteria treatment
- Extended drug treatment for life threatening infectionson August 1, 2022 at 2:52 am
Hospital patients who develop infections where 10% of sufferers die will be offered double the traditional course of antibiotics in a new trial.
- Bacterial Resistance to Antibiotics is Winning the Raceon July 22, 2022 at 10:33 pm
At this time it is essential to become aware of the resistance of the microbial population and the excessive use of antibiotics that are losing their effectiveness and usefulness.
- Indian Scientists Develop Novel Strategy For Revitalising Obsolete Antibiotics To Counter Multi-Drug Resistant Bacteriaon July 21, 2022 at 8:49 am
This strategy can combat the most critical group of bacteria enabling the existing antibiotic arsenal to be used again for complicated infections. It can help counter the rising menace of ...
- Raw Diet For Dogs? It May Make Pets More Likely To Carry Antibiotic-Resistant Bacteriaon July 20, 2022 at 7:03 pm
Putting dogs on a raw diet may have consequences pet parents aren't aware of. Researchers found evidence associating dogs' raw diet and the presence of antibiotic-resistant bacteria. A raw diet for ...
- Two-step process identifies bacterial infection quickly to help combat antibiotic resistanceon July 19, 2022 at 6:30 am
This is a growing and serious problem world-wide, because antibiotic resistant bacteria can spread from person to person and reduce treatment options. "The overuse of broad-spectrum antibiotics is ...